Veterinary biomarkers market seen topping $2B by 2030

By AI, Created 4:51 PM UTC, May 18, 2026, /AGP/ – The veterinary biomarkers market is projected to surpass $2 billion by 2030, with North America and the U.S. expected to lead growth. The forecast points to rising demand for faster diagnostics, precision medicine and point-of-care testing across companion and production animals.

Why it matters: - Veterinary biomarkers are moving from a niche diagnostic tool to a larger part of animal healthcare. - The market is forecast to exceed $2 billion by 2030, signaling growing demand for early detection and monitoring in pets and livestock. - The category is expected to take about 5% of the veterinary laboratory testing services market and nearly 0.6% of the broader veterinary healthcare market by 2030.

What happened: - The Business Research Company released a forecast for the global veterinary biomarkers market through 2030. - The report projects 12% CAGR for the market leading up to 2030. - North America is expected to be the largest region in 2030, valued at $0.55 billion. - The U.S. is projected to be the largest country in 2030, valued at $0.49 billion. - Kits and reagents are expected to be the largest product segment in 2030, at 53% of the market, or about $1 billion.

The details: - North America is projected to grow from $0.35 billion in 2025 to $0.55 billion in 2030, at a 10% CAGR. - U.S. market value is expected to rise from $0.31 billion in 2025 to $0.49 billion in 2030, also at a 10% CAGR. - The report links North American growth to higher pet ownership, rising animal healthcare spending, broader use of advanced diagnostics, stronger early-detection awareness and established veterinary infrastructure. - The U.S. outlook is tied to higher rates of chronic and infectious disease in companion animals, heavier diagnostic spending and wider use of biomarker-based testing in clinical decisions. - The veterinary biomarkers market is also segmented by disease type, animal type and application. - Disease categories include inflammatory and infectious diseases, cardiovascular diseases, skeletal muscle diseases, tumors and other diseases. - Animal segments include companion animals and production animals. - Application segments include disease diagnostics, preclinical research and other uses. - The report says the kits and reagents segment will benefit from routine use, simple handling and storage, faster test results, product innovation for multi-disease detection and expanding diagnostic labs. - The report includes a free sample request and a full report link.

Between the lines: - The forecast points to a shift toward more proactive veterinary care, where diagnostics are used earlier and more often. - AI-enabled in-clinic systems are expected to strengthen demand by combining biomarker analysis with real-time interpretation. - Chronic age-related diseases in dogs and cats are creating more need for ongoing monitoring rather than one-time testing. - Precision medicine and onco-fertility in companion animals suggest biomarker testing is becoming more specialized, not just more common.

What’s next: - The report expects AI-driven clinic workflows, chronic disease management and precision medicine to be the main demand drivers through 2030. - Biomarkers, kits and reagents, and biomarker readers are projected to add more than $0.7 billion in combined value by 2030. - Over the next five years, the biomarkers segment is projected to grow by $0.2 billion, kits and reagents by $0.4 billion and biomarker readers by $0.1 billion.

The bottom line: - Veterinary biomarkers are on track for steady double-digit growth as animal health providers lean harder on faster, more precise diagnostics.